AC Immune SA (NASDAQ: ACIU) and its partner Janssen Pharmaceuticals Inc have expanded the ongoing Phase 1b/2a trial evaluating anti-phosphorylated-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer's disease (AD).
The trial expansion specifically includes vaccination of additional AD patients at the second-highest dose.
In parallel, the trial continues to evaluate patients in the highest dose cohort, for which the first interim results will be available by the end of this year.
Interim Phase 1b/2a trial results from the low and second-highest dose groups showed vaccination generated a potent antigen-specific antibody response against pTau in 100% of older patients with early AD with no clinically relevant safety concerns observed to date.
In addition to ACI-35.030, AC Immune and Janssen Pharmaceuticals are evaluating an exploratory alternative pTau vaccine candidate, JACI-35.054, in the current Phase 1b/2a trial.
Price Action: ACIU shares are up 2.56% at $6.37 on the last check Monday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.